A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/08/2011	WO2011150855A1 Micro-rna biomarkers and methods for diagnosis of early colorectal carcinoma and high-grade adenoma
12/08/2011	WO2011150517A2 Biomarker for diagnosis and treatment of colorectal cancer
12/08/2011	WO2011150495A1 Rhamm binding peptides
12/08/2011	WO2011150494A1 Mitochondrial penetrating peptides as carriers for anticancer compounds
12/08/2011	WO2011150454A1 ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
12/08/2011	WO2011150453A1 Diagnostic, prognostic and therapeutic use of a long non-coding rna
12/08/2011	WO2011123946A8 Kinase inhibitors and method of treating cancer with same
12/08/2011	WO2011121453A3 Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
12/08/2011	WO2011103028A3 Compositions and methods for inhibiting mmset
12/08/2011	WO2011102999A3 Spink1 targeted therapy
12/08/2011	WO2011100460A3 Ccr7 ligand delivery and co-delivery in immunotherapy
12/08/2011	WO2011097381A8 Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
12/08/2011	WO2011072275A3 Agents and methods for treating ischemic and other diseases
12/08/2011	WO2011053991A3 Vault complexes for cytokine delivery
12/08/2011	WO2010124797A8 Anti-mesothelin immunoconjugates and uses therefor
12/08/2011	WO2010072741A9 TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREFOR
12/08/2011	US20110301697 Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open
12/08/2011	US20110301452 Microcapsule for local treatment of a tumor and method for positioning a magnetic gradient field guiding magnetic nanoparticles to a target location as well as apparatus for positioning a magnetic gradient field
12/08/2011	US20110301401 Compositions and methods for thermoradiotherapy
12/08/2011	US20110301339 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301338 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301337 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110301248 Compositions and methods of delivery of pharmacological agents
12/08/2011	US20110301236 HeLa-C3 Apoptosis Inducer from Garcinia paucinervis
12/08/2011	US20110301233 Novel Polyisoprenylated Benzophenone Derivatives from Garcinia paucinervis
12/08/2011	US20110301226 Compositions and methods for treating hepatic neoplasia
12/08/2011	US20110301222 Combination therapy for the treatment of cancer
12/08/2011	US20110301221 Diagnosis, prognosis and treatment of glioblastoma multiforme
12/08/2011	US20110301217 Selective Glycosidase Inhibitors and Uses Thereof
12/08/2011	US20110301216 Anticancer and antimicrobial compounds from antarctic extremophilic microorgansims
12/08/2011	US20110301212 Method for treating proliferative disorders associated with protooncogene products
12/08/2011	US20110301211 Antagonists of lysophosphatidic acid receptors
12/08/2011	US20110301209 Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
12/08/2011	US20110301203 Chemical compounds
12/08/2011	US20110301195 Triazolothiadiazole inhibitor of c-met protein kinase
12/08/2011	US20110301194 Method for Determining Treatment Efficacy
12/08/2011	US20110301193 Methods and compositions of targeted drug development
12/08/2011	US20110301192 Inhibitors of Cyclin Kinase Inhibitor p21
12/08/2011	US20110301189 Stable pharmaceutical compositions of rapamycin esters
12/08/2011	US20110301188 Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents
12/08/2011	US20110301187 Bis [o-(14-benzoylaconine-8-yl)] esters
12/08/2011	US20110301185 Cancer treatment method
12/08/2011	US20110301184 Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
12/08/2011	US20110301183 Chemical synthesis of a highly potent epothilone
12/08/2011	US20110301179 Naphthamides as anticancer agents
12/08/2011	US20110301177 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
12/08/2011	US20110301176 Imidazothiazole derivatives having proline ring structure
12/08/2011	US20110301175 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
12/08/2011	US20110301174 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
12/08/2011	US20110301173 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors
12/08/2011	US20110301169 Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites
12/08/2011	US20110301168 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
12/08/2011	US20110301163 Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
12/08/2011	US20110301162 Aurora kinase modulators and methods of use
12/08/2011	US20110301161 Benzimidazole inhibitors of leukotriene production
12/08/2011	US20110301159 Kinase inhibitor compounds
12/08/2011	US20110301157 Bicyclic amides as kinase inhibitors
12/08/2011	US20110301154 Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity
12/08/2011	US20110301153 Methods of treating cancer
12/08/2011	US20110301151 Dimeric iap inhibitors
12/08/2011	US20110301149 Compositions and methods for treating alcohol use disorders, pain and other diseases
12/08/2011	US20110301145 Pyridazinones, method of making, and method of use thereof
12/08/2011	US20110301144 Kinase Antagonists
12/08/2011	US20110301142 Antagonists of lysophosphatidic acid receptors
12/08/2011	US20110301134 Alkyne antagonists of lysophosphatidic acid receptors
12/08/2011	US20110301133 Compositions of protein receptor tyrosine kinase inhibitors
12/08/2011	US20110301130 Topical composition for the treatment of actinic keratosis
12/08/2011	US20110301128 Pyrrole Derivatives As Pharmaceutical Agents
12/08/2011	US20110301124 Proteasome inhibitors
12/08/2011	US20110301122 Heteroaromatic compounds for use as hif inhibitors
12/08/2011	US20110301113 Pyridineamine derivatives
12/08/2011	US20110301112 Fused ring thrombin receptor antagonists
12/08/2011	US20110301111 Cyclic adenosine monophosphates for reducing the formation of adhesions
12/08/2011	US20110301110 TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
12/08/2011	US20110301108 Materials and methods for sensitizing multidrug resistant cells
12/08/2011	US20110301104 Transition state structure of orotate phosphoribosyl transferases and uses thereof
12/08/2011	US20110301100 Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons
12/08/2011	US20110301097 Oral Administration Of Therapeutic Agent Coupled To Transporting Agent
12/08/2011	US20110301096 Prodrug of an ice inhibitor
12/08/2011	US20110301095 Methods and compositions for assessing and treating metastasis, metastatic cancer, and potential for metastasis
12/08/2011	US20110301094 New tumor suppressor gene, p28ing5
12/08/2011	US20110301093 Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1
12/08/2011	US20110301092 The use of a non-glycanated polypeptide for treating a cancer
12/08/2011	US20110301088 Crystalline ezatiostat hydrochloride ansolvate
12/08/2011	US20110301079 Neuromedin u receptor agonists and uses thereof
12/08/2011	US20110301077 Method for production of lactoferrin
12/08/2011	US20110301076 Antimicrobial compounds
12/08/2011	US20110300578 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110300577 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110300234 Methods of Treating Tumor Cells Using RHCC Protein, Fragment or Variant
12/08/2011	US20110300232 EFFECTS OF NITRIC OXIDE (NO) AND iNOS ON EXPRESSION AND SIGNAL TRANSDUCTION IN CANCER AND ITS USE IN DRUG DISCOVERY AND CANCER THERAPY DESIGN
12/08/2011	US20110300227 Malignant neoplasm treatment protocol
12/08/2011	US20110300219 Nanostructures for drug delivery
12/08/2011	US20110300213 Oral formulations of bipolar trans carotenoids
12/08/2011	US20110300199 Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions
12/08/2011	US20110300187 Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
12/08/2011	US20110300186 Functionalized Nano- and Micro-materials for Medical Therapies
12/08/2011	US20110300185 Immunogenic escherichia coli heat stable enterotoxin
12/08/2011	US20110300183 Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
12/08/2011	US20110300178 Hpv types and variants associated with cervical cancer and the uses thereof

1 ... 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 ... 2211